China-origin GLP-1s enter the global watchlist

Industry trackers have started following China-origin GLP-1 drugs such as mazdutide and ecnoglutide alongside the US and Danish candidates that have dominated headlines so far ^[1]. The shift became visible in June 2026, when high-dose mazdutide results were presented at the American Diabetes Association's Scientific Sessions and later summarized on the JAMA Medical News podcast ^[2].

Mazdutide is a dual glucagon and GLP-1 receptor agonist that is already approved for weight management in China, a country with the world's largest population living with overweight or obesity ^[2]. The new data come from the GLORY-2 trial, which tested a 9 mg dose of injectable mazdutide over 60 weeks in 461 adults in China with overweight or obesity, average BMI 34, of whom 16% also had type 2 diabetes ^[2]. Participants on the higher dose lost 15.1% of body weight more than those on placebo, and the group also saw reductions in systolic blood pressure, triglycerides and non-HDL cholesterol, according to Rita Kalyani, MD, chief scientific and medical officer of the American Diabetes Association ^[2].

Ecnoglutide is named in the same watchlist entry as mazdutide, but the source material gives no trial results, dosing or approval status for it ^[1]. Industry coverage groups both drugs under "China-origin agonists" tracked for future approvals and data, alongside a separate set of newer Western candidates including zenagamtide, survodutide and pemvidutide ^[1]. That tracker is explicitly cross-referenced to broader coverage of Asian biopharma development, signaling that analysts see this as part of a wider pattern rather than a single company's news ^[1].

The development lands in a month already crowded with GLP-1 news. The same August 2026 tracking period recorded the UK's first-in-Europe authorization of oral orforglipron (Foundayo) for weight management and type 2 diabetes, mixed 68-week results for Novo Nordisk's CagriSema against tirzepatide in the REIMAGINE 4 trial, and confirmation that Eli Lilly's retatrutide data package is complete ahead of a planned US filing ^[1]. Amgen also discontinued an early obesity candidate, AMG 513, leaving MariTide as its only late-stage obesity drug ^[1].

Why it matters for patients

For now, mazdutide and ecnoglutide are not approved or sold in the United States, and the sources do not describe any US regulatory filing, target date or clinical trial site for either drug. Their relevance to American patients is indirect: they signal that more companies, in more countries, are working on GLP-1 and related dual-agonist drugs, which over time can affect how many options reach the US market and how quickly. The mazdutide data also add to the broader evidence base on dual glucagon/GLP-1 agonists as a drug class, even though the specific trial population was in China, with a different average BMI and diabetes mix than typical US obesity trials.

Patients currently using or considering semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound) or orforglipron (Foundayo) should not expect any near-term change in their own treatment because of this news. It is not yet known whether mazdutide or ecnoglutide will be studied or filed for approval in the United States, or on what timeline.

What happens next

The sources describe mazdutide and ecnoglutide as items on a standing monthly watchlist for "approvals and data," without a stated US filing date ^[1]. Meanwhile, other pipeline events already have firmer dates: a US Food and Drug Administration decision on CagriSema is expected by late 2026, and Eli Lilly has said it plans to submit retatrutide to the FDA in the first quarter of 2027 ^[1]. No comparable US regulatory timeline exists yet for the Chinese candidates in these sources.